Prelude Therapeutics annual working capital
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Working Capital Growth & History (PRLD)
Prelude Therapeutics's working capital was $52.7M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $52.7M | −$57.6M | −52.20% |
| 2024 | 2024-12-31 | $110.3M | −$103.5M | −48.42% |
| 2023 | 2023-12-31 | $213.8M | $31.1M | +17.01% |
| 2022 | 2022-12-31 | $182.7M | −$93.2M | −33.79% |
| 2021 | 2021-12-31 | $275.9M | $66.5M | +31.74% |
| 2020 | 2020-12-31 | $209.4M | $194.0M | +1260.93% |
| 2019 | 2019-12-31 | $15.4M | — | — |
Prelude Therapeutics quarterly working capital
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $116.9M | $60.9M | +108.79% |
| Q1 2026 | 2026-03-31 | $42.9M | −$39.7M | −48.11% |
| Q4 2025 | 2025-12-31 | $52.7M | −$57.6M | −52.20% |
| Q3 2025 | 2025-09-30 | $40.1M | −$94.0M | −70.08% |
| Q2 2025 | 2025-06-30 | $56.0M | −$103.4M | −64.88% |
| Q1 2025 | 2025-03-31 | $82.6M | −$105.1M | −55.99% |
| Q4 2024 | 2024-12-31 | $110.3M | −$103.5M | −48.42% |
| Q3 2024 | 2024-09-30 | $134.2M | −$83.9M | −38.46% |
| Q2 2024 | 2024-06-30 | $159.4M | −$85.6M | −34.95% |
| Q1 2024 | 2024-03-31 | $187.7M | $32.1M | +20.64% |
| Q4 2023 | 2023-12-31 | $213.8M | $31.1M | +17.01% |
| Q3 2023 | 2023-09-30 | $218.0M | $12.7M | +6.18% |
| Q2 2023 | 2023-06-30 | $245.0M | $12.2M | +5.24% |
| Q1 2023 | 2023-03-31 | $155.6M | −$98.3M | −38.72% |
| Q4 2022 | 2022-12-31 | $182.7M | −$93.2M | −33.79% |
| Q3 2022 | 2022-09-30 | $205.3M | −$100.9M | −32.95% |
| Q2 2022 | 2022-06-30 | $232.8M | −$97.1M | −29.43% |
| Q1 2022 | 2022-03-31 | $253.9M | −$98.7M | −27.99% |
| Q4 2021 | 2021-12-31 | $275.9M | $66.5M | +31.74% |
| Q3 2021 | 2021-09-30 | $306.2M | $79.5M | +35.08% |
| Q2 2021 | 2021-06-30 | $329.9M | — | — |
| Q1 2021 | 2021-03-31 | $352.6M | — | — |
| Q4 2020 | 2020-12-31 | $209.4M | $194.0M | +1260.93% |
| Q3 2020 | 2020-09-30 | $226.7M | — | — |
| Q4 2019 | 2019-12-31 | $15.4M | — | — |
Prelude Therapeutics working capital trends
Over the last five fiscal years, Prelude Therapeutics's working capital decreased from $209.4M to $52.7M, a change of −$156.7M. The latest reported quarter, Q2 2026, shows $116.9M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...